Status:
COMPLETED
Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children
Lead Sponsor:
Clarteis
Conditions:
Vitiligo
Pediatric ALL
Eligibility:
All Genders
4-18 years
Phase:
NA
Brief Summary
Vitiligo is a auto immune that impact 2% of the global population, regardless from the phototype. Even though it affects patients in a physical way through loss of pigmentation, it is also impacting t...
Eligibility Criteria
Inclusion
- vitiligo and surface area involved of less than10% who are being followed in the outpatient dermatology clinics of King Abdullah University Hospital (KAUH)
- 6 weeks wash out period from previous treatments will be employed to eliminate any effect from such treatments
Exclusion
- Skin dermatoses with Kobner phenomenon
- Lupus erythematous
- Pacemakers
- Hyper-photosensitivity
- Melanoma and non-melanoma skin cancers
- Drugs with photosensitizer side effect
- Radiotherapy
- Pregnancy (by principle, nno study available)
- Diseases that are contagious by contact
Key Trial Info
Start Date :
October 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06035614
Start Date
October 1 2022
End Date
July 1 2023
Last Update
September 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Abdullah University Hospital
Ar Ramtha, Jordan, 21410